Current treatment at multiple myeloma / 白血病·淋巴瘤

ABSTRACT

The breakthrough progress has been made in the treatment of multiple myeloma.Since 1990 s,autologous stem-cell transplantation (ASCT) has resulted in high response rate of MM,and the median overall survival was 5 years.The recent introduction of the novel agents including thalidomide,bortezomib,and lenalidomide further increase the response rate of MM.It is reported that the median overall survival was increased by 50 ％.The latest estimates of the median overall survival was about 10 years in under 65 years old patients,and 5-6 years in the elderly patients.The novel agents under investigation will further prolong the overall survival rate and progression free survival in the near future.